Agomelatine is a melatonergic antidepressant manufactured by the French pharmceutical company, Servier. It is also a weak antagonist of certain serotonin receptors. A new study indicates that agomelatine accelerates the progression of Parkinson's and worsens symptoms of the disease, like dyskinesia in laboratory rats. Autopsies of the brains of the rats show markers of increased inflammation, oxidative stress and loss of cells in the striatum. Here is the study: https://www.ncbi.nlm.nih.gov/pubmed/30716425 This merits consideration for those thinking about using AM as na antidepressant, especially for those with a tendency for Parkinson's.
Last edited by a moderator: